EORTC-1203-GITCG - the "INNOVATION"-trial: Effect of chemotherapy alone versus chemotherapy plus trastuzumab, versus chemotherapy plus trastuzumab plus pertuzumab, in the perioperative treatment of HER2 positive, gastric and gastroesophageal junction adenocarcinoma on pathologic response rate: a randomized phase II-intergroup trial of the EORTC-Gastrointestinal Tract Cancer Group, Korean Cancer Study Group and Dutch Upper GI-Cancer group

Anna Dorothea Wagner; Heike Grabsch; Murielle Mauer; Sandrine Marreaud; Carmela Caballero; Peter Thuss-Patience; Lothar Mueller; Annelie Elme; Markus Hermann Moehler; Uwe Martens; Yoon-Koo Kang; Sun Young Rha; Annemieke Cats; Masanori Tokunaga; Florian Lordick

doi:10.1186/s12885-019-5675-4

EORTC-1203-GITCG - the "INNOVATION"-trial: Effect of chemotherapy alone versus chemotherapy plus trastuzumab, versus chemotherapy plus trastuzumab plus pertuzumab, in the perioperative treatment of HER2 positive, gastric and gastroesophageal junction adenocarcinoma on pathologic response rate: a randomized phase II-intergroup trial of the EORTC-Gastrointestinal Tract Cancer Group, Korean Cancer Study Group and Dutch Upper GI-Cancer group

Anna Dorothea Wagner^*, Heike Grabsch, Murielle Mauer, Sandrine Marreaud, Carmela Caballero, Peter Thuss-Patience, Lothar Mueller, Annelie Elme, Markus Hermann Moehler, Uwe Martens, Yoon-Koo Kang, Sun Young Rha, Annemieke Cats, Masanori Tokunaga, Florian Lordick

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

Original language	English
Article number	494
Number of pages	9
Journal	BMC Cancer
Volume	19
DOIs	https://doi.org/10.1186/s12885-019-5675-4
Publication status	Published - 24 May 2019

Keywords

Gastric cancer
Gastro-esophageal junction cancer
Perioperative chemotherapy
Trastuzumab
Pertuzumab
HER2
NEOADJUVANT CHEMOTHERAPY
BREAST-CANCER
OPEN-LABEL
CAPECITABINE
OXALIPLATIN
REGRESSION
DOCETAXEL
SURGERY

Cite this

Wagner, A. D., Grabsch, H., Mauer, M., Marreaud, S., Caballero, C., Thuss-Patience, P., Mueller, L., Elme, A., Moehler, M. H., Martens, U., Kang, Y-K., Rha, S. Y., Cats, A., Tokunaga, M., & Lordick, F. (2019). EORTC-1203-GITCG - the "INNOVATION"-trial: Effect of chemotherapy alone versus chemotherapy plus trastuzumab, versus chemotherapy plus trastuzumab plus pertuzumab, in the perioperative treatment of HER2 positive, gastric and gastroesophageal junction adenocarcinoma on pathologic response rate: a randomized phase II-intergroup trial of the EORTC-Gastrointestinal Tract Cancer Group, Korean Cancer Study Group and Dutch Upper GI-Cancer group. BMC Cancer, 19, [494]. https://doi.org/10.1186/s12885-019-5675-4

Wagner, Anna Dorothea ; Grabsch, Heike ; Mauer, Murielle ; Marreaud, Sandrine ; Caballero, Carmela ; Thuss-Patience, Peter ; Mueller, Lothar ; Elme, Annelie ; Moehler, Markus Hermann ; Martens, Uwe ; Kang, Yoon-Koo ; Rha, Sun Young ; Cats, Annemieke ; Tokunaga, Masanori ; Lordick, Florian. / EORTC-1203-GITCG - the "INNOVATION"-trial : Effect of chemotherapy alone versus chemotherapy plus trastuzumab, versus chemotherapy plus trastuzumab plus pertuzumab, in the perioperative treatment of HER2 positive, gastric and gastroesophageal junction adenocarcinoma on pathologic response rate: a randomized phase II-intergroup trial of the EORTC-Gastrointestinal Tract Cancer Group, Korean Cancer Study Group and Dutch Upper GI-Cancer group. In: BMC Cancer. 2019 ; Vol. 19.

@article{920598a2c958435c910fcf3c2fe92335,

title = "EORTC-1203-GITCG - the {"}INNOVATION{"}-trial: Effect of chemotherapy alone versus chemotherapy plus trastuzumab, versus chemotherapy plus trastuzumab plus pertuzumab, in the perioperative treatment of HER2 positive, gastric and gastroesophageal junction adenocarcinoma on pathologic response rate: a randomized phase II-intergroup trial of the EORTC-Gastrointestinal Tract Cancer Group, Korean Cancer Study Group and Dutch Upper GI-Cancer group",

keywords = "Gastric cancer, Gastro-esophageal junction cancer, Perioperative chemotherapy, Trastuzumab, Pertuzumab, HER2, NEOADJUVANT CHEMOTHERAPY, BREAST-CANCER, OPEN-LABEL, CAPECITABINE, OXALIPLATIN, REGRESSION, DOCETAXEL, SURGERY",

author = "Wagner, {Anna Dorothea} and Heike Grabsch and Murielle Mauer and Sandrine Marreaud and Carmela Caballero and Peter Thuss-Patience and Lothar Mueller and Annelie Elme and Moehler, {Markus Hermann} and Uwe Martens and Yoon-Koo Kang and Rha, {Sun Young} and Annemieke Cats and Masanori Tokunaga and Florian Lordick",

year = "2019",

month = may

day = "24",

doi = "10.1186/s12885-019-5675-4",

language = "English",

volume = "19",

journal = "BMC Cancer",

issn = "1471-2407",

publisher = "BioMed Central Ltd",

}

Wagner, AD, Grabsch, H, Mauer, M, Marreaud, S, Caballero, C, Thuss-Patience, P, Mueller, L, Elme, A, Moehler, MH, Martens, U, Kang, Y-K, Rha, SY, Cats, A, Tokunaga, M & Lordick, F 2019, 'EORTC-1203-GITCG - the "INNOVATION"-trial: Effect of chemotherapy alone versus chemotherapy plus trastuzumab, versus chemotherapy plus trastuzumab plus pertuzumab, in the perioperative treatment of HER2 positive, gastric and gastroesophageal junction adenocarcinoma on pathologic response rate: a randomized phase II-intergroup trial of the EORTC-Gastrointestinal Tract Cancer Group, Korean Cancer Study Group and Dutch Upper GI-Cancer group', BMC Cancer, vol. 19, 494. https://doi.org/10.1186/s12885-019-5675-4

EORTC-1203-GITCG - the "INNOVATION"-trial : Effect of chemotherapy alone versus chemotherapy plus trastuzumab, versus chemotherapy plus trastuzumab plus pertuzumab, in the perioperative treatment of HER2 positive, gastric and gastroesophageal junction adenocarcinoma on pathologic response rate: a randomized phase II-intergroup trial of the EORTC-Gastrointestinal Tract Cancer Group, Korean Cancer Study Group and Dutch Upper GI-Cancer group. / Wagner, Anna Dorothea; Grabsch, Heike; Mauer, Murielle; Marreaud, Sandrine; Caballero, Carmela; Thuss-Patience, Peter; Mueller, Lothar; Elme, Annelie; Moehler, Markus Hermann; Martens, Uwe; Kang, Yoon-Koo; Rha, Sun Young; Cats, Annemieke; Tokunaga, Masanori; Lordick, Florian.

In: BMC Cancer, Vol. 19, 494, 24.05.2019.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - EORTC-1203-GITCG - the "INNOVATION"-trial

T2 - Effect of chemotherapy alone versus chemotherapy plus trastuzumab, versus chemotherapy plus trastuzumab plus pertuzumab, in the perioperative treatment of HER2 positive, gastric and gastroesophageal junction adenocarcinoma on pathologic response rate: a randomized phase II-intergroup trial of the EORTC-Gastrointestinal Tract Cancer Group, Korean Cancer Study Group and Dutch Upper GI-Cancer group

AU - Wagner, Anna Dorothea

AU - Grabsch, Heike

AU - Mauer, Murielle

AU - Marreaud, Sandrine

AU - Caballero, Carmela

AU - Thuss-Patience, Peter

AU - Mueller, Lothar

AU - Elme, Annelie

AU - Moehler, Markus Hermann

AU - Martens, Uwe

AU - Kang, Yoon-Koo

AU - Rha, Sun Young

AU - Cats, Annemieke

AU - Tokunaga, Masanori

AU - Lordick, Florian

PY - 2019/5/24

Y1 - 2019/5/24

KW - Gastric cancer

KW - Gastro-esophageal junction cancer

KW - Perioperative chemotherapy

KW - Trastuzumab

KW - Pertuzumab

KW - HER2

KW - NEOADJUVANT CHEMOTHERAPY

KW - BREAST-CANCER

KW - OPEN-LABEL

KW - CAPECITABINE

KW - OXALIPLATIN

KW - REGRESSION

KW - DOCETAXEL

KW - SURGERY

U2 - 10.1186/s12885-019-5675-4

DO - 10.1186/s12885-019-5675-4

M3 - Article

VL - 19

JO - BMC Cancer

JF - BMC Cancer

SN - 1471-2407

M1 - 494

ER -

Wagner AD, Grabsch H, Mauer M, Marreaud S, Caballero C, Thuss-Patience P et al. EORTC-1203-GITCG - the "INNOVATION"-trial: Effect of chemotherapy alone versus chemotherapy plus trastuzumab, versus chemotherapy plus trastuzumab plus pertuzumab, in the perioperative treatment of HER2 positive, gastric and gastroesophageal junction adenocarcinoma on pathologic response rate: a randomized phase II-intergroup trial of the EORTC-Gastrointestinal Tract Cancer Group, Korean Cancer Study Group and Dutch Upper GI-Cancer group. BMC Cancer. 2019 May 24;19. 494. https://doi.org/10.1186/s12885-019-5675-4

Access to Document

10.1186/s12885-019-5675-4